The UK and US have reached a significant trade agreement that will keep zero duties on British drug products being sold in the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the NHS. This pledge guarantees that duties on these crucial products will stay at zero for a duration of the next three years.
This deal is in response to recent warnings to significantly raise tariffs on branded drug products, with increases discussed reaching one hundred percent.
"This deal with the UK bolsters the global environment for innovative medicines and brings much-needed fairness to American-British medicine commerce," a release said.
Trade Importance
Pharmaceuticals are one of the the United Kingdom's largest exports to the United States, which is by far the biggest destination for leading UK drugmakers.
Trade data show that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products valued at billions to the US. This figure made up a significant portion of total UK exports in that period.
"This deal secures employment, stimulates funding and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall public funding on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, rebates topped twenty percent.
Broader Context
This agreement comes amid a protracted tension between the sector and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by assertions that American patients were charged several times more for the same drugs than people in the other developed nations.
Recently, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had declined as a percentage of its overall budget over the previous ten-year period.
